John Kauh will present a poster at the CHEST 2024 Annual Meeting – AIM-HI Accelerator Fund

AIM-HI Accelerator Fund recently shared about John Kauh presenting a poster at the CHEST 2024 Annual Meeting. Read the post on LinkedIn below:

“Exciting Update!

AIM-HI portfolio company, Tvardi Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, announced that John Kauh, M.D., Chief Medical Officer, will present a poster at the American College of Chest Physicians (CHEST) 2024 Annual Meeting, which is being held October 6-9, in Boston, Massachusetts.

Learn More.”

John Kauh is the Chief Medical Officer at Tvardi Therapeutics and a board-certified medical oncologist with experience in drug development and regulatory submissions in the U.S. and EU. Previously, he was Vice President of Clinical Development at HUTCHMED, overseeing clinical trials from Phase 1 to Phase 3.